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Background: The effectiveness and safety of switch from oral oxycodone to fentanyl patch is little known. Here, we
investigated if early phase opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch
provided any benefits for patients with thoracic malignancy and stable cancer-related pain.
Methods: This open-label two-centered prospective study enrolled patients with thoracic malignancy suffering
persistent malignancy-related pain with numeric rating scale of pain intensity≤ 3 which had been controlled by oral
oxycodone ≤ 20 mg/day. Eligible patients switched from oral oxycodone to 12.5 μg/h of transdermal fentanyl matrix
patch. The dose was allowed to be titrated upwards every 3 day by 25-50%, except for the first increase from
12.5 μg/hr to 25 μg/hr,until achieving adequate pain control. The data on patients’ global assessment scores
measured on a five-step scale, an 11-point numeric rating scale of pain intensity, the severity of adverse effects using a
four-point categorical rating scale, and the Epworth sleepiness scale questionnaire were collected for 15 days.
Results: Forty-nine eligible patients were analyzed. Overall patients’ satisfaction score significantly improved from day 1
(2.7 ± 0.9) to day 15 (2.3 ± 0.9) (p < 0.05), and 90% and 78% of patients remained to receive the minimum dose of
fentanyl patch on day 8 and 15 from the opioid switch. There was a significant difference in sleepiness throughout the
study period, though no difference was detected in pain intensity and other adverse effects.
Conclusion: Transdermal fentanyl matrix patch is an alternative analgesic option for a stable cancer pain in patients
with thoracic malignancies.
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Cancer-related pain is the most important concern in pa-
tients suffering cancer. More than 80% of patients with
advanced disease experience cancer-related pain caused
largely by direct tumor invasion [1]. Cancer-related pain
often disturbs activities of daily living and deteriorates
quality-of-life [2].
Opioids are the mainstay of analgesic therapy for mod-
erate to severe cancer-related pain, according to the current
guidelines [1,3]. Oxycodone, a semi-synthetic opioid* Correspondence: tkijima@imed3.med.osaka-u.ac.jp
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unless otherwise stated.analgesic, has become a cornerstone in symptom manage-
ment of cancer-related pain [4-6]. Controlled-release of
oxycodone is often administered as the first-line strong
opioid, typically at an initial dose of 5-10 mg every
12 hours in opioid-naïve patients, when non-steroidal
anti-inflammatory drugs (NSAIDs) and weak opioids
are ineffective.
On the other hand, the high lipid solubility and low
molecular weight of fentanyl is suitable for transdermal
administration. In 2002, a transdermal therapeutic system
(TTS) for fentanyl incorporating a gel reservoir technol-
ogy was first marketed as the Durotep®Patch (Janssen-
Pharma, Japan). In 2008, a transdermal fentanyl matrix
patch (Durotep®MT patch, Janssen-Pharma, Japan), a new
TTS that contains fentanyl dissolved in the adhesion layer,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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matrix patch, with fentanyl release rates of 12.5 μg/h,
makes it possible to switch from lower dose of other
opioid and then gradually titrate to the effectual dose
[7]. Fentanyl may has not only a powerful analgesic ef-
fect, but advantage of less frequent and milder adverse
effects such as nausea, vomiting, constipation and sleepi-
ness [8-12]. Compared with oral morphine, fentanyl may
have advantage especially in constipation, but there are
concerns over methodological problems of constipation
assessment. In a crossover trial, constipation was less fre-
quent under transdermal fentanyl than under oral mor-
phine, though the assessment methods of constipation
remained unclear [9]. In another comparison study, the
use of laxatives given by nurses was investigated instead of
assessment of constipation and shown to be less frequent
in fentanyl [12]. Two meta-analyses [13,14] and a system-
atic review [15] also indicated a significant reduction in
constipation for fentanyl patch compared with oral mor-
phine. In contrast, another prospective comparison study
showed that transdermal opioids of fentanyl and bupre-
norphine had no benefit over controlled release oral
hydromorphone in gastrointestinal symptoms including
constipation [16]. However, the evidence on an advan-
tage of fentanyl patch over oral opioids is low level, be-
cause the trials regarding fentanyl patch were limited, not
blinded and of low methodological quality [3].
Opioid switch is a therapeutic maneuver aiming at im-
provement of analgesic response and reduction of adverse
effects [17]. The maneuver includes change to different
medication using the same administration route, alteration
of administration route maintaining the current medica-
tion, or both. Fentanyl patch is the most favorable candi-
date of opioid switch from oral opioids because of less
adverse effects and easier administration route [9,10,18,19].
Switch from oral morphine to transdermal fentanyl patch
was shown as an effective and safe method [9,10], though
the drop-out rate with fentanyl was higher than that with
morphine in a crossover trial [9]. In contrast, little is
known about the benefits of switch from oral oxycodone
to fentanyl patch.
In this study, we investigated if early phase opioid
switch from low dose of oral oxycodone to transdermal
fentanyl matrix patch provided any benefits for patients
with stable cancer-related pain.
Methods
Patient eligibility
Patients with thoracic malignancy-related pain were re-
cruited in Osaka Police Hospital and Osaka University
Hospital. The patients who met all the following criteria
were eligible; 1) confirmed diagnosis of thoracic malig-
nancy, 2) age ≥ 20 years, 3) persistent malignancy-related
pain refractory to non-steroidal anti-inflammatory drugs(NSAIDs) or acetaminophen, 4) numeric rating scale
(NRS) for pain ≤ 3 for at least two consecutive days by low
dose (20 mg/day or less) of oral oxycodone (Oxycontine®,
Shionogi-Pharma, Japan). Exclusion criteria were as fol-
lows; 1) prior history of allergy or hypersensitivity to
opioids, 2) prior history of opioid abuse, 3) clinically
significant cardiac, renal or hepatic insufficiency, 4) in-
creased intracranial pressure or impaired cognitive
function, 5) active and extensive skin disease precluding
application of the transdermal delivery system, 6) per-
sistent fever of 40 degrees Celsius or over, 7) pregnancy,
lactation and suspicion of being pregnant, 8) prior use
of any opioid-antagonists within 2 days before switching
to fentanyl patch. Concomitant treatments such as
chemotherapy and radiotherapy at the enrollment were
accruable.
Study design and treatment
All patients recorded the following data daily for 15 days
of fentanyl patch treatment; 1) pain intensity using an
11-point NRS (scales 0–10), 2) the severity of adverse ef-
fects (e.g., nausea, vomiting, constipation and sleepiness)
using a four-point categorical rating scale (none = 0, not
hard = 1, hard but endurable = 2 and unendurably hard =
3), 3) the number of defecation per day, 4) the Epworth
sleepiness scale (ESS) questionnaire except for the ques-
tion on sleepiness during driving a car because strong
opioids are not permitted for drivers in Japan, 5) the fre-
quencies of immediate-release oxycodone (Oxinorm®,
Shionogi-Pharma, Japan) medications per day. Time of
recording diary was arbitrary. The diaries were collected
after 15 days of fentanyl patch treatment. The patients'
global assessment scores were also rated using a five-
step scale (very satisfied = category 1, satisfied = 2, nei-
ther satisfied nor dissatisfied = 3, dissatisfied = 4 and
very dissatisfied = 5) [20] on days 1, 8 and 15. Oral oxy-
codone was switched to 12.5 μg/h of transdermal fen-
tanyl matrix patch. In the morning on the switch day
(day 1), a fentanyl patch (2.1 mg/3 days) was applied at
the same time of the oral intake of the last controlled-
release oxycodone dose. Rescue immediate-release oxy-
codone dose to relieve the breakthrough pain was adjusted
according to the dose of transdermal fentanyl patch. The
dose of transdermal fentanyl patch was allowed to be ti-
trated upwards every 3 days by 25-50%, except for the first
increase from 2.1 mg/patch (12.5 μg/hr) to 4.2 mg/patch
(25 μg/hr), until patients could achieve adequate pain con-
trol. Transdermal fentanyl patch treatment was continued
for 15 days (5 replacements). Neither addition nor dose
change of other supplementary analgesics was permitted
during the study.
The primary endpoint in this study was patients' global
assessment scores. Secondary endpoints were pain inten-
sity, adverse effects and use of rescue oxycodone.
Table 1 Patients’ characteristics (N = 49)
Sex
Male/Female 43/6
Age (years-old) 69.0 ± 6.9
Body mass index (kg/m2) 20.4 ± 4.9
Cancer (Histology)








Lower back/Glutaeus to thigh
4/2/32/1/7/5
Pain causesb
Distant metastasis (bone)/Invasion/Pleural dissemination
22 (17)/18/11
Duration of cancer pain (months)
mean ± SD 4.3 ± 4.4
median (range) 2 (0.27–18)
Duration of controlled-release oxycodone administration (months)
mean ± SD 2.0 ± 4.3
median (range) 0.6 (0.1 − 19.7)











Ad, Adenocarcinoma; SQ, Squamous cell carcinoma; SCLC, Small cell lung
carcinoma; ECOG PS, European Clinical Oncology Group Performance status;
SD, standard deviation.
aincluding a case with malignant mesothelioma in c-stage IV.
bThere were two overlapping.
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Review Board of Osaka University Hospital and the
Osaka Police Hospital ethics committee, adhered to the
principles outlined in the Guideline for Good Clinical
Practice (January 1997) and Declaration of Helsinki (1996),
and registered as UMIN000011067. Written informed con-
sent was obtained from all patients before commencement
of the study.
Statistical analysis
We expected that 85% of patients would give the global
assessment scores 1 to 3, on the basis of the data from a
previous Japanese clinical trial of Durotep®MT patch
reporting that the patients’ satisfaction was 89.4% [20].
The estimated number of patients for analysis was 49
with a confidence interval of 95% and β-error of 10%.
Given the possibility of deviation from assessment, 60
patients were necessary.
Listwise deletion was adopted in cases in which we
missed data at opioid switch (day 1). Patients who
dropped out without completion of 15-day patch treat-
ment were also deleted from analysis. Missing data at
days 8 and 15 from opioid switch were handled using
last observation carried forward (LOCF) imputation
technique.
The data for normally distributed continuous variables,
discrete variables, and categorical variables are expressed
as the mean ± standard deviation (SD), median with range,
and frequency. Friedman test, with a post-hoc Steel test,
was used to compare longitudinal changes in numeric and
categorical rating scales and ESS questionnaire scores.
Significance was set at p < 0.05. All statistical analyses
were performed using Statcel statistical package (Statcel3;
OMS Inc., Tokorozawa, Japan).
Results
Although enrollment to this study was planned to complete
within 2 years, only 50 patients were accrued for 4 years,
despite of 2-year extension of the study period. Therefore,
this study was terminated in December 2012 because of
delayed accrual. The final accrual did not reach 60 pa-
tients, the preplanned sample size.
From February 2009 to December 2012, a total of 50
eligible patients switched opioids. Almost all patients
completed 15 days of fentanyl matrix patch treatment
except one patient who suddenly died of cancer progres-
sion on the 13rd day from opioid switch. During the
study period, 51% and 24% of patients concomitantly re-
ceived chemotherapy and radiotherapy, respectively. The
baseline characteristics are shown in Table 1.
Overall patients’ satisfaction was significantly different
throughout the study period (Friedman test; p < 0.01).
The proportion of patients in category 1 or 2 (‘very satis-
fied’ or ‘satisfied’) for the patient's global assessmentscore increased from 43% on day 1 to 63% on day 8 and
61% on day 15, while the proportion of patients in cat-
egory 1–3 (‘very satisfied’, ‘satisfied’ or ‘neither satisfied
nor dissatisfied’) hardly changed from 87% on day 1 to
91% on day 15 (Table 2).
Oxycodone doses on day 1 differed from 10 to 20 mg/day.
Fentanyl matrix patch dose remained 12.5 μg/h in 44
patients (90%) on day 8 and 38 patients (78%) on day
Table 2 Change of patients’ global assessment scores
(N = 46 a)
Day 1 Day 8 Day 15
mean ± SD 2.7 ± 0.9 2.4 ± 0.9 2.3 ± 0.9
median (range) 3 (1 − 5) 2 (1 − 5) 2 (1 − 5)
vs. day 1b n.s. n.s.
Patients’ distribution (N)
1. Very satisfied 2 5 9
2. Satisfied 18 24 19
3. Neither 20 12 14
4. Dissatisfied 4 4 3
5. Very dissatisfied 2 1 1
aThree patients were excluded from analysis because of missing data
throughout all the three observation points.
bPost-hoc nonparametric multiple comparison analysis was performed using
Steel method after significant difference in assessment scores across multiple
points was detected by Freidman test (p < 0.01).
n.s.; not significant (p > 0.05).
SD; standard deviation.
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(20%) during the study period (Table 3). Six, eight and six
patients felt pain with NRS ≥ 4 at day 1, 8 and 15, respect-
ively. Among them, one, two and two patients were under
outpatient care at day 1, 8 and 15, respectively. There was
no significant difference between 3 measurement days in
pain intensity, rescue dose of oxycodone and adverse ef-
fects except sleepiness (Friedman test, p = 0.01) (Tables 4
and 5 and Additional file 1: Table S1).
Discussion
This is the first study to evaluate opioid switch directly
from low dose of oral oxycodone to fentanyl matrix
patch in patients with malignancy-related pain.
Another Japanese study also investigated opioid switch
to 12.5 μg/h of fentanyl matrix patch from various opi-
oids. This study was different from ours in the following
three points; 1) including various kinds of prior opioid;
oral oxycodone < 30 mg/day (69.4%), intravenous fentanyl




Mean ± SD 14.7 ± 4.1 mg/day
Patients’ distribution (N) 10 mg/day 18
15 mg/day 16
20 mg/day 15
All patients were switched from oral oxycodone to 12.5 μg/h of fentanyl matrix pat
*Half-side application procedure of fentanyl matrix patch was not defined in our pr
SD; standard deviation.intravenous morphine (29.4%), 2) recruiting patients
with various types of primary cancers, including 34% of
respiratory cancer, 3) assessing patients’ global pain assess-
ment only at day 10, during third patch application, or the
day of protocol withdrawal [20]. We focused on switch
only from oral oxycodone ≤ 20 mg/day, recruited only pa-
tients with thoracic malignancy, and compared patients’
global assessments among 3 measurement days.
The most important finding of our study was that pa-
tients’ satisfaction was improved by opioid switch from
oral oxycodone to fentanyl patch. More than 80% of pa-
tients did not feel dissatisfied in the patients' global as-
sessment scores, which met the primary endpoint.
Contrast to no difference in ESS score, sleepiness was
significantly improved by opioid switch. Moreover, favor-
able changes were conceivably noted in constipation,
though the improvement in constipation did not reach
statistical significance. In the four-point categorical rat-
ing scale of sleepiness (scales 0 − 3), the number of pa-
tients with scale 0 increased from 6 on day 1 up to 19
on day 15, while that with scale 1 decreased from 29
down to 20. In the assessment of constipation, all 5 pa-
tients with scale 2 or 3 on day 1 improved to scale 0 or
1 on day 15, while one patient with scale 0 on day 1 de-
teriorated into scale 2 on day 15 (Additional file 1: Table
S1). These changes were similar to those in the study by
Miyazaki et al., in which the rate of ‘very satisfied’ and
‘satisfied’ increased over time after opioid switch to fen-
tanyl patch [20].
The second important finding was that conversion rate
from oral oxycodone to fentanyl patch was not uniform.
In our study, various doses of oral oxycodone from 10 to
20 mg/day were switched uniformly to 12.5 μg/h of fen-
tanyl patch. Not a few patients felt pain of NRS ≥ 4 and
needed increase of fentanyl patch thereafter. The equiva-
lent dose of fentanyl patch to oral oxycodone was not
definite in our study, though an initial conversion from
10-20 mg/day of oral oxycodone to 12.5 μg/h of fentanyl
patch seems safe and reasonable. Thus, we have to pay
careful attention to switch from oral oxycodone totrix patch at day 0, 8 and 15 (N = 49)
Day 8 Day 15
Fentanyl patch Fentanyl patch
13.7 ± 4.8 μg/h 15.5 ± 6.0 μg/h
12.5 μg/h 44 12.5 μg/h 38
18.8 μg/h* 1 18.8 μg/h* 1
25.0 μg/h 3 25.0 μg/h 9
37.5 μg/h 1 37.5 μg/h 1
ch at day 1.
otocol.
Table 4 Change of numeric rating scale (NRS) of pain intensity and use of rescue immediate-release oxycodone
Day 1 Day 8 Day 15 p-valuea
NRS pain intensity (N = 49) 0.15
Mean ± SD 2.2 ± 1.4 2.1 ± 1.5 1.9 ± 1.4
Median (range) 2 (0 − 6) 2 (0 − 7) 2 (0 − 6)
NRS 0 – 3 / ≥ 4 43/6 41/8 43/6
Immediate-release oxycodone (mg / day) (N = 48)b 0.36
Mean ± SD 1.9 ± 2.2 2.7 ± 3.5 2.2 ± 2.7
Median (range) 2.5 (0 − 10) 2.5 (0 − 15) 1.75 (0 − 10)
SD; standard deviation.
aFriedman test.
bOne patient was excluded from analysis of rescue use because of missing data throughout all the three observation points. The remaining 48 patients completed
data collection.
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Our study included some limitations. First, our study
was not blinded. A bias derived from different formula-
tions was possible. Second, we used an unvalidated tool
to assess constipation, thereby this adverse event might
be either underestimated or overestimated. Third, more
than half patients concomitantly received other cancer
treatment such as chemotherapy or radiotherapy. Be-
cause these concomitant treatments possibly influenced
cancer pain, the true analgesic power of fentanyl patch
was uncertain in those patients. Considering the poorTable 5 Adverse events
N Day 1
Sleepiness 45
Mean ± SD 1.2 ± 0.7
Median (range) 1 (0 − 3)
vs. day 1b
Nausea 49
Mean ± SD 0.4 ± 0.8
Median (range) 0 (0 − 3)
Vomit 49
Mean ± SD 0.1 ± 0.6
Median (range) 0 (0 − 3)
Constipation 48
Mean ± SD 0.5 ± 0.7
median (range) 0 (0 − 3)
Defecation number (/ day) 49
Mean ± SD 1.1 ± 1.0
Median (range) 1 (0 − 4)
Epworth Sleep Scale 49
Mean ± SD 6.3 ± 4.0
Median (range) 6 (0 − 16)
SD; standard deviation, n.s.; not significant (p > 0.05).
aFriedman test.
bPost-hoc nonparametric multiple comparison analysis was performed using Steel m
was detected by Freidman test (p = 0.01).prognosis of advanced lung cancer, we could not forbid
any other cancer treatments during the study period.
Fourth, the day 1 at opioid switch might not be appro-
priate as a baseline assessment for comparison with day
8 and 15. In addition, we should have standardized the
timing of diary record. Although all patients had re-
ported pain of NRS ≤ 3 until the previous day of opioid
switch, six patients suffered from pain of NRS level ≥ 4
at the day of opioid switch (on day1). Five of these 6 pa-
tients converted opioids on day1 in our hospitals, and
recorded their diaries on day 1 before or at the same
time as the first application of fentanyl patch. BecauseDay 8 Day 15 p-valuea
0.004
0.9 ± 0.6 0.73 ± 0.8
1 (0 − 2) 1 (0 − 3)
n.s. <0.05
0.87
0.4 ± 0.7 0.3 ± 0.6
0 (0 − 3) 0 (0 − 2)
0.66
0.2 ± 0.6 0.1 ± 0.5
0 (0 − 3) 0 (0 − 2)
0.08
0.3 ± 0.5 0.3 ± 0.5
0 (0 − 2) 0 (0 − 2)
0.85
1.0 ± 0.8 1.0 ± 0.7
1 (0 − 4) 1 (0 − 4)
0.96
6.1 ± 4.2 6.0 ± 4.2
5 (0 − 18) 5 (0 − 19)
ethod after significant difference in assessment scores across multiple points
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had written diaries on day 1 at home, this patient might
have severer pain than usual by the confusion from oral
oxycodone to fentanyl patch. Fifth, we did not grasp the
precise number of ineligible patients who dropped out
during oxycodone treatment due to uncontrollable pain
by 20 mg/day of oral oxycodone. Thus, we failed to clarify
the proportion of eligible patients for this opioid switch
maneuver in all patients with thoracic malignancy-related
pain requiring strong opioid. Based on the study limita-
tions described above, we are considering a cross-over
trial comparing in pain control and adverse severity be-
tween fentanyl patch and oral opioid for cancer-related
pain, instead of a randomized blinded controlled trial. Our
study group is still too small to conduct such a high level
of trial.
Conclusion
Transdermal fentanyl matrix patch is an alternative an-
algesic option for a stable cancer pain in patients with
thoracic malignancies.
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